CONCENTRATION	12 Months Ended
Jul. 31, 2023
CONCENTRATION
CONCENTRATION	NOTE 6 – CONCENTRATION Revenue During the year ended July 31,2022, the Company entered in a consulting agreement in the field of Healthcare for monthly payments of $8,333 with First DP Ventures, LP. The services were performed by a member of the Company’s board of directors. As of July 31, 2023, and 2022, all revenue of $100,001 and $41,666 and accounts receivable of $8,333 and $8,332, was received from one customer, respectively. Cost of revenue During the years ended July 31, 2023 and 2022, the cost of revenue of $94,629 and $38,214, respectively, was for the payroll expenses related to a member of the Company’s board of directors, who performed the consulting agreement‘s services.

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 275
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//275/tableOfContent

Name:	us-gaap_ConcentrationRiskDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration